Ennov Recognized by Gartner in the 2021 Hype Cycle for Life Sciences R&D

July 19, 2021

Ennov is Recognized in 5 Different Technology Areas

Ennov today announced it has been recognized five times by Gartner as a vendor in the 2021 “Hype Cycle for Life Science Research and Development”.

This recognizes the relevance of Ennov’s products in Clinical, Regulatory and Pharmacovigilance domains. Ennov is acknowledged for our solutions in the following product categories:

  • AI-Augmented Safety Vigilance
  • SaaS-Regulated CSP
  • eTMF
  • E-Clinical Platforms
  • Global Regulatory Information Management

About the 2021 Hype Cycle for Life Sciences

The 2021 Hype Cycle explores innovative technologies relevant to life science R&D product development programs in the pharmaceutical, biotechnology, diagnostics, medical device, research institution and contract research sectors.

About Gartner

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Ennov

Headquartered in Paris, with offices in Raleigh, NC and Cambridge, UK, Ennov provides the most cost effective, comprehensive and user-friendly solutions for regulated content and process management for the Life Sciences industry. Our suite of software solutions is built on our unified compliance platform and is being used by over 150 Life Sciences companies and more than 250,00 users worldwide.

*Hype Cycle for Life Science Research and Development, 2021
Published: 19 July 2021
Analyst(s): Jeff Smith, Michael Shanler

Share :


Register for free to access to our library of exclusive content!

Highlight Post

Recent Posts